News

  • USPTOHouseLetter-12-1-21-logo AIPLA Comments on Patent Center and the Retirement of EFS-Web and Private PAIR

    October 30, 2023

    Arlington, VA. October 30, 2023 - The American Intellectual Property Law Association (AIPLA) submitted comments to the US Patent and Trademark Office (USPTO) on the upcoming transition to Patent Center as a replacement for EFS-Web and Private PAIR by the USPTO.
  • TermDisc-Comments-March21-logo AIPLA Files Amicus Brief in The TriZetto Group, Inc. v. Syntel Sterling Best Shores Mauritius Limited

    October 24, 2023

    On October 18, 2023, the American Intellectual Property Law Association (AIPLA) filed an amicus brief in support of a petition for certiorari to the Supreme Court in The TriZetto Group, Inc. v. Syntel Sterling Best Shores Mauritius Limited (23-306) on the issue of whether unjust enrichment damages in a trade secret case should be considered independently of the victim’s own loss.
  • gaylord-national-header-2020-tb American Intellectual Property Law Association Announces New Board Members and Award Recipients at 2023 Annual Meeting

    October 23, 2023

    ARLINGTON, Virginia - The American Intellectual Property Law Association (AIPLA) hosted the 2023 Annual Meeting from October 19-21, at the Gaylord National Resort & Convention Center in National Harbor, Maryland, where new board members were sworn in for the 2023-2024 year and ten awards were presented to deserving recipients.
  • TermDisc-Comments-March21-logo AIPLA Co-Signs Letter in Support of NDAA Provisions

    October 16, 2023

    On September 14, 2023, AIPLA co-signed a letter in support of Senator Chuck Grassley's NDAA provisions regarding CBP authority to disclose enforcement information.
  • AIPLA Files Amicus Brief with Court of Appeals for the Federal Circuit in In re: Xencor, Inc.

    October 16, 2023

    On October 6, 2023, the American Intellectual Property Law Association (AIPLA) filed an amicus brief with the Court of Appeals for the Federal Circuit in In re: Xencor, Inc., a case on appeal from the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board. The case concerns the Board’s rejection of patent claims directed to a treatment method involving administration of an antibody containing certain amino acid substitutions that increase the antibody’s half-life. The Board rejected the claims for lack of written description and as indefinite.